Home > Insider Trading > Filing (0001359824-17-000005)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1195116	Arno Therapeutics Inc	ARNI	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1044734	Donald S Sussman	888 E. Las Olas Blvd. Suite 210 Ft Lauderdale FL 33301		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2016-12-30	4,285,111	$0.00	714,285	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	2012 Series A Warrants	Disposition	2016-12-30	1,605,809	$0.00	1,605,809	$1.14
Common Stock	2013 Series D Warrants	Disposition	2016-12-30	1,383,702	$0.00	1,383,702	$1.75

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2013-10-29	2017-11-26	No	4	S	Direct
0	2013-10-29	2018-10-29	No	4	S	Direct

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	2016 Series F Warrants (right to buy)	$0.44	2016-08-15	2021-08-15	357,142	357,142	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2021-08-15	357,142	357,142	Direct

Footnotes

Commercial Street Capital LLC ("CSC") has a contractual right to designate one member of the Issuer's board of directors and has designated Steven B. Ruchefsky, a director of the Issuer, pursuant to such right. Accordingly, the Reporting Person, as a co-managing director of CSC, may be deemed to be a director by deputization for purposes of Section 16 of the Exchange Act.
These shares of common stock or warrants exercisable for shares of common stock, as applicable, represent a pro rata distribution from CSC, and not a purchase or sale, of such shares or warrants by CSC to its members without consideration.
These reported securities are included within a sale by the Reporting Person of all such securities for an aggregate price of $1,000.
As a result of the Issuer's 8/15/16 private placement of common stock and Series F Warrants, the exercise prices and shares underlying the 2012 Series A Warrants and 2013 Series D Warrants were automatically adjusted to the exercise price and shares reflected pursuant to anti-dilution adjustment provisions in such warrants.